查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268889

活生物治疗产品和微生物组 CDMO 市场规模、份额、趋势分析报告，按应用（艰难梭菌、克罗恩病、IBS、糖尿病）、按地区、按细分市场预测，2023-2030 年

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C.difficle, Crohns Disease, IBS, Diabetes), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

活体生物治疗产品和微生物组 CDMO 的市场增长和趋势：

Grand View Research, Inc. 的一份新报告显示，到 2030 年的预测期内，全球活体生物治疗产品和微生物组 CDMO 市场规模的复合年增长率将达到 41.3%，预计将达到 358.07 美元百万到 2020 年。

近年来，微生物组 CDMO 和活生物治疗产品 (LBP) 的市场迅速扩大，预计这一趋势将持续下去。 患者和医疗保健提供者越来越意识到活的生物治疗产品和基于微生物组的疗法在治疗多种疾病（包括炎症性肠病、癌症和神经系统疾病）方面的潜在益处。它是为了

致力于这些领域的 CDMO 的需求是由製药和生物技术公司增加对活体生物治疗产品和微生物药物的投资推动的，预计这一趋势将在未来十年持续。 随着 LBP 和微生物衍生疗法市场的扩大，公司正在寻找具有开发和製造这些产品所需技能的 CDMO。 因此，全球 CDMO 市场正在扩大，预计未来几年将大幅扩大。 随着这些治疗开髮变得越来越复杂，外包给 CDMO 正在成为製药和生物技术公司的一个有吸引力的选择。

活性生物治疗产品和基于微生物的疗法根据用途进行市场细分，目前艰难梭菌类别在市场上占主导地位。 迫切需要有效的药物来解决復发性艰难梭菌感染这一主要且日益严重的健康问题。 例如，由 Seres Therapeutics 创建的用于治疗復发性艰难梭菌感染的微生物组疗法 SER-109 在临床试验中显示出积极的结果。 FDA 将 SER-109 归类为突破性疗法，如果获得批准，该公司将成为艰难梭菌感染市场的重要竞争对手。 由于对有效治疗艰难梭菌和其他疾病的需求不断增长，活生物治疗产品和微生物药物市场有望发展。

COVID-19 大流行对活生物治疗产品市场和微生物组合同研究与製造组织 (CDMO) 产生了重大影响。 大流行造成的中断导致临床试验延迟、对某些产品的需求减少以及供应链中断。 然而，随着大流行病相关法规的放鬆以及医疗保健成为人们更加关注的焦点，预计 LBP 和基于微生物的疗法市场将在未来几年復苏。 该领域的公司将需要适应新的挑战并找到创新的解决方案以在大流行后的世界中维持增长。

活体生物治疗产品和微生物组 CDMO 市场报告要点：

  • 艰难梭菌占最大的收入份额，2022 年的复合年增长率最快。 艰难梭菌感染的流行率上升以及对有效治疗的需求不断增长正在推动市场增长。 许多公司都专注于开发和製造用于治疗艰难梭菌感染的产品，以推动市场的扩张。
  • 北美占据最大的市场份额，这主要是因为该地区存在主要参与者以及研发活动的投资增加。 此外，对艰难梭菌、克罗恩病和 IBS 等各种疾病的有效治疗需求的增加也有助于北美市场的扩张。

内容

第一章调查方法及范围

  • 市场细分和范围
    • 服务
    • 最终用途
    • 估计/预测时间表
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场形成和验证
  • 模型详细信息
    • 产品流分析（模型 1）
    • 批量价格分析（模型 2）
  • 次要信息列表
  • 主要信息列表
  • 目的

第 2 章执行摘要

  • 市场展望

第 3 章活生物治疗产品和微生物组 CDMO 市场 (CSO) 变量、趋势和范围

  • 市场体系展望
    • 母公司市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
      • 与外包相关的质量问题
    • COVID-19 的影响和恢復分析
    • 行业分析 - 搬运工
    • PESTLE 分析

第 4 章活生物治疗产品和微生物组 CDMO 市场 (CSO)：按应用细分

  • 活生物治疗产品和微生物组 CDMO 市场 (CSO) 市场：定义和范围
  • 活生物治疗产品和微生物组 CDMO 市场 (CSO) 市场：服务市场份额分析，2022 年和 2030 年
    • 艰难梭菌
      • 克罗恩病
      • 肠易激综合征
      • 糖尿病
      • 其他

第 5 章活生物治疗产品和微生物组 CDMO 市场 (CSO)：区域分析

  • 活生物治疗产品和微生物组 CDMO 市场 (CSO)：区域市场份额分析，2022 年和 2030 年
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第六章竞争格局

  • 阿兰特简介
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 4D 製药
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 塞比奥斯
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 生物产业
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • Assembly Biosciences, Inc.
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 瓦克化学股份公司
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 码头製药
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 尼佐
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 龙沙
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • Inpac 益生菌
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
Product Code: GVR-4-68040-061-6

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 358.07 million by 2030, registering a CAGR of 41.3% over the forecast period, according to a new report by Grand View Research, Inc. The market for microbiome CDMOs and Live Biotherapeutic Products (LBPs) has been growing quickly in recent years, and this trend is anticipated to continue. the rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows.This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years. Outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies due to the increasing complexity of developing these therapies.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, SER-109, a microbiome therapy created by Seres Therapeutics for the treatment of recurrent C. difficile infection, has demonstrated good outcomes in clinical trials. The FDA has given the business SER-109's breakthrough therapy classification; if approved, this would position the company as a significant contender in the market for C. difficile medicines. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has had a significant impact on the market for live biotherapeutic products and microbiome Contract Development and Manufacturing Organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

  • C.difficle holds the largest revenue share and fastest CAGR in 2022. The increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the market. Many companies are focusing on developing and manufacturing products for the treatment of C.difficle infections, driving the market's expansion
  • North America has dominated the market with the largest market share, primarily due to the presence of key players and increasing investments in research and development activities in this region. The growing demand for effective treatments for various diseases such as C.difficile, Crohn's disease, and IBS, has also contributed to the market growth in North America

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Service
    • 1.1.2. End use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Quality issues associated with outsourcing
    • 3.2.3. Covid-19 Impact & Recovery Analysis
    • 3.2.4. Industry Analysis - Porter's
    • 3.2.5. PESTLE Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Application Segment Analysis

  • 4.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Definition & Scope
  • 4.2. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Service Market Share Analysis, 2022 & 2030
    • 4.2.1. C.difficle
      • 4.2.1.1. C.difficle market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Crohns disease
      • 4.2.1.2.1. Crohns disease market, 2018 - 2030 (USD Million)
      • 4.2.1.3. IBS
      • 4.2.1.3.1. IBS market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Diabetes
      • 4.2.1.4.1. Diabetes market, 2018 - 2030 (USD Million)
      • 4.2.1.5. Others
      • 4.2.1.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional Analysis

  • 5.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional market share analysis, 2022 & 2030
  • 5.2. North America
    • 5.2.1. North America Market estimates and forecast, 2018 - 2030
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
    • 5.2.3. Canada
      • 5.2.3.1. Canada Market estimates and forecast, 2018 - 2030
  • 5.3. Europe
    • 5.3.1. Europe Market estimates and forecast, 2018 - 2030
    • 5.3.2. UK
      • 5.3.2.1. UK Market estimates and forecast, 2018 - 2030
    • 5.3.3. Germany
      • 5.3.3.1. Germany Market estimates and forecast, 2018 - 2030
    • 5.3.4. France
      • 5.3.4.1. France Market estimates and forecast, 2018 - 2030
    • 5.3.5. Italy
      • 5.3.5.1. Italy Market estimates and forecast, 2018 - 2030
    • 5.3.6. Spain
      • 5.3.6.1. Spain Market estimates and forecast, 2018 - 2030
    • 5.3.7. Denmark
      • 5.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
    • 5.3.8. Sweden
      • 5.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
    • 5.3.9. Norway
      • 5.3.9.1. Norway Market estimates and forecast, 2018 - 2030
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
    • 5.4.2. Japan
      • 5.4.2.1. Japan Market estimates and forecast, 2018 - 2030
    • 5.4.3. China
      • 5.4.3.1. China Market estimates and forecast, 2018 - 2030
    • 5.4.4. India
      • 5.4.4.1. India Market estimates and forecast, 2018 - 2030
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
    • 5.4.6. Australia
      • 5.4.6.1. Australia Market estimates and forecast, 2018 - 2030
    • 5.4.7. Thailand
      • 5.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
  • 5.5. Latin America
    • 5.5.1. Latin America Market estimates and forecast, 2018 - 2030
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
    • 5.5.3. Mexico
      • 5.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
    • 5.5.4. Argentina
      • 5.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
  • 5.6. `MEA
    • 5.6.1. MEA Market estimates and forecast, 2018 - 2030
    • 5.6.2. South Africa
      • 5.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
    • 5.6.4. UAE
      • 5.6.4.1. UAE Market estimates and forecast, 2018 - 2030
    • 5.6.5. Kuwait
      • 5.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Arrant Bio
    • 6.1.1. Company overview
    • 6.1.2. Financial performance
    • 6.1.3. Service benchmarking
    • 6.1.4. Strategic initiatives
  • 6.2. 4D Pharma
    • 6.2.1. Company overview
    • 6.2.2. Financial performance
    • 6.2.3. Service benchmarking
    • 6.2.4. Strategic initiatives
  • 6.3. Cerbios
    • 6.3.1. Company overview
    • 6.3.2. Financial performance
    • 6.3.3. Service benchmarking
    • 6.3.4. Strategic initiatives
  • 6.4. Biose Industrie
    • 6.4.1. Company overview
    • 6.4.2. Financial performance
    • 6.4.3. Service benchmarking
    • 6.4.4. Strategic initiatives
  • 6.5. Assembly Biosciences, Inc
    • 6.5.1. Company overview
    • 6.5.2. Financial performance
    • 6.5.3. Service benchmarking
    • 6.5.4. Strategic initiatives
  • 6.6. Wacker Chemie AG
    • 6.6.1. Company overview
    • 6.6.2. Financial performance
    • 6.6.3. Service benchmarking
    • 6.6.4. Strategic initiatives
  • 6.7. Quay Pharmaceuticals
    • 6.7.1. Company overview
    • 6.7.2. Financial performance
    • 6.7.3. Service benchmarking
    • 6.7.4. Strategic initiatives
  • 6.8. NIZO
    • 6.8.1. Company overview
    • 6.8.2. Financial performance
    • 6.8.3. Service benchmarking
    • 6.8.4. Strategic initiatives
  • 6.9. LONZA
    • 6.9.1. Company overview
    • 6.9.2. Financial performance
    • 6.9.3. Service benchmarking
    • 6.9.4. Strategic initiatives
  • 6.10. Inpac Probiotics
    • 6.10.1. Company overview
    • 6.10.2. Financial performance
    • 6.10.3. Service benchmarking
    • 6.10.4. Strategic initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Live Biotherapeutic Products and Microbiome CDMO outlook, 2018 - 2030
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Live Biotherapeutic Products and Microbiome CDMO : Application outlook key takeaways
  • FIG. 15 Live Biotherapeutic Products and Microbiome CDMO : Application movement analysis
  • FIG. 16 C.difficle market, 2018 - 2030 (USD Million)
  • FIG. 17 Crohns disease market, 2018 - 2030 (USD Million)
  • FIG. 18 IBS market, 2018 - 2030 (USD Million)
  • FIG. 19 Diabetes market, 2018 - 2030 (USD Million)
  • FIG. 20 Others market, 2018 - 2030 (USD Million)
  • FIG. 21 Regional market place: Key takeaway
  • FIG. 22 Live Biotherapeutic Products and Microbiome CDMO regional outlook, 2020 & 2028
  • FIG. 23 North America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 24 U.S. Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 25 Canada Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 26 Europe Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 27 Germany Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 28 France Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 29 UK Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 30 Spain Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 31 Italy Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 32 Denmark Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 33 Sweden Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 34 Norway Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 35 Asia Pacific Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 36 China Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 37 Japan Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 38 India Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 39 Thailand Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 40 South Korea Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 41 Australia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 42 Latin America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 43 Brazil Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 44 Mexico Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 45 Argentina Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 46 Middle East & Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 47 South Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 48 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 49 UAE Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 50 Kuwait Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)